試す - 無料

Trump Can't Turn US Statistics Into Banana Republic Numbers

Mint Mumbai

|

August 14, 2025

Rejecting inconvenient economic data doesn't change what it says

- DANIEL MOSS

Trump Can't Turn US Statistics Into Banana Republic Numbers

One of Jimmy Carter's top aides was banned from talking about recessions or depressions. So the head of the campaign against US inflation in the late 1970s came to describing downturns as "bananas." Bendy food is again fashionable in economic parlance.

Banana-republic governance has been evoked to describe US President Donald Trump's firing of the government's top labor statistician after a poor jobs report and threats against the head of the Federal Reserve for not lowering interest rates faster. The Oval Office's disdain for anything considered bad news and the instinct to dispose of those who deliver it, is not only corrosive, but sets a bad example.

Not that long ago, the argument for countries in dire straits was to become like America. Certainly, that was the message that much of Asia received a generation ago. Now, the world ought to look in horror. If favorability is the benchmark by which numbers are considered credible, then the global economy will be flying without a pilot. Investors from Singapore to New York depend on the authority of reports that indicate the direction of prices, employment and growth. And they trust what comes out of the US more than just about anywhere else.

Mint Mumbai からのその他のストーリー

Mint Mumbai

Mint Mumbai

Gen Alpha will make new rules for their workplace

Gen Alpha will expect hybrid workplaces, Al tools and 4-day weeks— offices unrecognizable to their parents’

time to read

3 mins

December 01, 2025

Mint Mumbai

EC extends electoral roll revision by a week to II Dec; final list on 14 Feb

The Election Commission on Sunday extended by one week the entire schedule of the ongoing special intensive revision (SIR) of electoral rolls in nine states and three Union territories amid allegations by opposition parties that the “tight timelines” were creating problems for people and ground-level poll officials.

time to read

2 mins

December 01, 2025

Mint Mumbai

THE PROBLEM IS NOT JUST ABOUT DYNASTIC POLITICS

These days Tejashvi Yadav is the target of intense trolling. Before him the Huda family in Haryana and Thackerays in Maharashtra got the same treatment. So, is the battle of victory and defeat in electoral politics a tussle between dynasts vs the rest? Absolutely not.

time to read

3 mins

December 01, 2025

Mint Mumbai

Mint Mumbai

Green hydrogen: Fast fashion could help bump up demand

A boom in its use for clean synthetic inputs might make a difference

time to read

3 mins

December 01, 2025

Mint Mumbai

Let's be a bit more selective in using the word 'reforms'

Everybody should take a beat and think before uttering the word ‘reforms’ the next time. Glib usage, frequently in the wrong context, threatens to rob the word of its import.

time to read

3 mins

December 01, 2025

Mint Mumbai

As mid-cap alpha shrinks, should you consider passive strategies?

Advisers urge a balanced mix—add passives slowly and back strong, active managers, as mid-caps are still pricey

time to read

4 mins

December 01, 2025

Mint Mumbai

Mint Mumbai

With $2.2 bn fund, ChrysCap has appetite for riskier bets

MD Saurabh Chatterjee details shift in global LP base, renewed focus on manufacturing

time to read

3 mins

December 01, 2025

Mint Mumbai

GDP growth of 8% plus: How to sustain this pace

Last quarter's economic expansion has cheered India but the challenge is to sustain a brisk rate for years to come. For private investment to chip in, revive infrastructure partnerships

time to read

2 mins

December 01, 2025

Mint Mumbai

INSIDE INDIA'S ATTEMPT TO TAME DEEPFAKES

Detection tools today are not universal or consistent across languages

time to read

5 mins

December 01, 2025

Mint Mumbai

Mint Mumbai

APIs to innovation: Bulk drug makers ramp up CDMO bets

Once focused on low-margin active pharmaceutical ingredients (APIs), India’s bulk drug manufacturers are raising their ambitions, with several now investing heavily in research and development to win contract development and manufacturing work from global drugmakers.

time to read

2 mins

December 01, 2025

Listen

Translate

Share

-
+

Change font size